Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease.

Frontiers in immunology·2023
Same author

STING Is Required in Conventional Dendritic Cells for DNA Vaccine Induction of Type I T Helper Cell- Dependent Antibody Responses.

Frontiers in immunology·2022
Same author

B cell activating factor (BAFF) from neutrophils and dendritic cells is required for protective B cell responses against Salmonella typhimurium infection.

PloS one·2021
Same author

Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.

Journal of medicinal chemistry·2021
Same author

BAFF Produced by Neutrophils and Dendritic Cells Is Regulated Differently and Has Distinct Roles in Antibody Responses and Protective Immunity against West Nile Virus.

Journal of immunology (Baltimore, Md. : 1950)·2020
Same author

Reactivity patterns of class I HLA monoclonal antibodies that distinguish three species of macaques.

American journal of primatology·2020
Same journal

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same journal

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 17, 2009

STALing B cell responses with CD22.

Craig P Chappell1, Edward A Clark

  • 1Department of Immunology, University of Washington, Seattle, Washington 98195, USA.

The Journal of Clinical Investigation
|June 1, 2013
PubMed
Summary
This summary is machine-generated.

New research offers a way to suppress harmful autoantibody production without weakening the entire immune system. This novel approach targets specific antibody responses, preserving the body

More Related Videos

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 6, 2010

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Related Experiment Videos

Last Updated: May 10, 2026

Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 17, 2009

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 6, 2010

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Area of Science:

  • Immunology
  • Autoimmunity
  • Therapeutic Development

Background:

  • Current therapies for autoimmune diseases often involve broad immunosuppression, leading to side effects.
  • Harmful autoantibody production is a hallmark of many autoimmune conditions.
  • There is a need for targeted therapies that selectively inhibit pathogenic autoantibodies.

Purpose of the Study:

  • To develop a novel platform for inhibiting antigen-specific antibody production.
  • To preserve the host's immune response to foreign pathogens while suppressing autoantibodies.
  • To overcome the limitations of conventional immunosuppressive therapies.

Main Methods:

  • Utilized a novel platform to target and inhibit antigen-specific antibody production.
  • Evaluated the platform's ability to suppress unwanted humoral immune responses.
  • Assessed the preservation of immune response to unrelated antigens.

Main Results:

  • Demonstrated successful inhibition of antigen-specific antibody production.
  • Showcased the platform's ability to maintain immune competence against foreign antigens.
  • Indicated a potential for selective immune modulation.

Conclusions:

  • The novel platform effectively suppresses antigen-specific antibody production.
  • This approach offers a promising strategy for treating autoimmune diseases with reduced off-target effects.
  • Preserves host immunity, addressing a key limitation of current treatments.